Lower dose of Neurocrine’s movement disorder drug fails in study

(Reuters) – Neurocrine Biosciences Inc said a lower dose of its experimental drug to treat a rare movement disorder did not meet the main goal of a mid-stage clinical study, sending its shares down 32 percent in after-market trade. A number of analysts, including those from Jefferies, Oppenheimer, Roth and Zacks, had been upbeat on the prospects of the drug, NBI-98854, being developed to treat tardive dyskinesia — a disorder that causes involuntary, repetitive body movements. Most of the enthusiasm was because there is no available treatment for the disorder yet. …